IMUNON Reports Third Quarter 2025 Financial Results And Provides Business Update. R&D Day showcased remarkable Investigator optimism, continued strengthening supportive data, and significant progress ...

IMUNON (IMNN) announced that it has been invited to present a trials-in-progress abstract on the ongoing Phase 3 OVATION 3 clinical trial of IMNN-001, its investigational therapy for the treatment of ...

On November 10, 2025, Imunon, Inc. (NASDAQ:IMNN) held an R&D day that featured presentations from ovarian cancer thought leaders and principal investigators from the Phase 3 OVATION 3 study and Phase ...

This price reflects trading activity during the overnight session on the Blue Ocean ATS, available 8 p.m. to 4 a.m. ET, Sunday through Thursday, when regular markets are closed. Chart does not reflect ...

Get the latest insider transactions for Imunon, Inc. (IMNN). Find out the total of insider shares held, purchased and sold.

Two studies suggest that T cells with stem-cell-like properties could work with antibody therapies to control HIV after a ...